Center for Population Health Information Technology, Department of Health Policy and Management, The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.
Department of Pharmacy, The Johns Hopkins Hospital, Baltimore, MD.
J Manag Care Spec Pharm. 2022 Apr;28(4):473-484. doi: 10.18553/jmcp.2022.28.4.473.
Patient effort to comply with complex medication instructions is known to be related to nonadherence and subsequent medical complications or health care costs. A widely used Medication Regimen Complexity Index (MRCI) has been used with electronic health records (EHRs) to identify patients who could benefit from pharmacist intervention. A similar claims-derived measure may be better suited for clinical decision support, since claims offer a more complete view of patient care and health utilization. To define and validate a novel insurance claims-based medication complexity score (MCS) patterned after the widely used MRCI, derived from EHRs. Insurance claims and EHR data were provided by HealthPartners (N = 54,988) (Bloomington, Minnesota) and The Johns Hopkins Health System (N = 28,589) (Baltimore, Maryland) for years 2013 and 2017, respectively. Yearly measures of medication complexity were developed for each patient and evaluated with one another using rank correlation within different clinical subgroupings. Indicators for the presence of individually complex prescriptions were also developed and assessed using exact agreement. Complexity measures were then correlated with select covariates to further validate the concordance between MCS and MRCI with respect to clinical metrics. These included demographic, comorbidity, and health care utilization markers. Prescribed medications in each system's EHR were coded using the previously validated MRCI weighting rules. Insurance claims for retail pharmacy medications were coded using our novel MCS, which closely followed MRCI scoring rules. EHR-based MRCI and claims-based MCS were significantly correlated with one another for most clinical subgroupings. Likewise, both measures were correlated with several covariates, including count of active medications and chronic conditions. The MCS was, in most cases, more associated with key health covariates than was MRCI, although both were consistently significant. We found that the highest correlation between MCS and MRCI is obtained with patients who have similar counts of pharmacy records between EHRs and claims (HealthPartners: = 0.796; Johns Hopkins Health System: = 0.779). The findings suggest good correspondence between MCS and MRCI and that claims data represent a useful resource for assessing medication complexity. Claims data also have major practical advantages, such as interoperability across health care systems, although they lack the detailed clinical context of EHRs. The Johns Hopkins University holds the copyright to the Adjusted Clinical Groups (ACG) system and receives royalties from the global distribution of the ACG system. This revenue supports a portion of the authors' salary. No additional or external funding supported this work. The authors have no conflict of interest to disclose.
患者遵守复杂药物医嘱的努力与不依从和随后的医疗并发症或医疗保健成本有关。广泛使用的药物治疗方案复杂性指数(MRCI)已与电子健康记录(EHR)一起用于识别可能受益于药剂师干预的患者。类似的基于索赔的措施可能更适合临床决策支持,因为索赔提供了更完整的患者护理和健康利用视图。
定义并验证一种新的基于保险索赔的药物复杂性评分(MCS),该评分模式源自广泛使用的 MRCI,源自 EHR。
保险索赔和 EHR 数据由 HealthPartners(N=54988)(明尼苏达州布卢明顿)和 The Johns Hopkins Health System(N=28589)(马里兰州巴尔的摩)分别于 2013 年和 2017 年提供。为每个患者制定了年度药物复杂性衡量标准,并使用不同临床分组内的秩相关进行了相互评估。还开发并使用完全一致评估了存在个体复杂处方的指标。然后将复杂性衡量标准与选定的协变量相关联,以进一步验证 MCS 与 MRCI 在临床指标方面的一致性。这些指标包括人口统计学、合并症和医疗保健利用标志物。每个系统的 EHR 中的规定药物均使用经过验证的 MRCI 加权规则进行编码。零售药房药物的保险索赔使用我们的新 MCS 进行编码,该编码规则紧密遵循 MRCI 评分规则。
EHR 中的基于 MRCI 和基于索赔的 MCS 与大多数临床分组高度相关。同样,这两个措施都与多个协变量相关,包括活跃药物的数量和慢性疾病。在大多数情况下,MCS 与关键健康协变量的相关性高于 MRCI,尽管两者均始终具有显着意义。我们发现,MCS 与 MRCI 之间的相关性最高是在 EHR 和索赔之间具有相似药房记录数量的患者中(HealthPartners:=0.796;约翰霍普金斯健康系统:=0.779)。
研究结果表明,MCS 和 MRCI 之间具有良好的对应关系,并且索赔数据代表评估药物复杂性的有用资源。索赔数据还具有互操作性等主要实际优势,可在医疗保健系统之间使用,尽管它们缺乏 EHR 的详细临床背景。
约翰霍普金斯大学拥有调整后的临床分组(ACG)系统的版权,并从全球范围内分发 ACG 系统中获得版税。这笔收入支持作者部分工资。这项工作没有其他或外部资金支持。作者没有利益冲突需要披露。